ar3998 1478-6354 Meeting abstract <p>Nonlymphoma hematological malignancies in systemic lupus erythematosus</p> LuM Ramsey-GoldmanR BernatskyS PetriM ManziS UrowitzMB GladmanD FortinPR GinzlerE YelinE BaeS-C WallaceDJ JacobsenS DooleyMA PeschkenCA AlarcónGS NivedO GottesmanL CriswellL SturfeltG DreyerL LeeJL ClarkeAE

Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada

Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Johns Hopkins University School of Medicine, Baltimore, MD, USA

West Penn Allegheny Health System, Pittsburgh, PA, USA

Toronto Western Hospital, Toronto, ON, Canada

Division of Rheumatology, Université de Laval, QC, Canada

State University of New York - Downstate Medical Center, Brooklyn, NY, USA

Division of Rheumatology, University of California San Francisco, San Francisco, CA, USA

The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea

Cedars-Sinai Medical Center/David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

University of Manitoba, Winnipeg, MB, Canada

The University of Alabama, Birmingham, AL, USA

Lund University Hospital, Lund, Sweden

Rigshospitalet and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark

 Arthritis Research & Therapy <p>Lupus 2012: New targets, new approaches</p>Peter E Lipsky, John M Esdaile, Matthew H Liang and Paul R FortinMeeting abstracts<p>Lupus 2012: New targets, new approaches</p>Whistler, Canada27-30 September 20121478-6354 2012 14 Suppl 3 A64 http://arthritis-research.com/content/14/S3/A64 10.1186/ar3998 2792012 2012Lu et al.; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective

To describe nonlymphoma hematological malignancies in systemic lupus erythematosus (SLE).

Methods

An international, multisite (n = 28) SLE cohort was linked to regional tumor registries. We examined the types of nonlymphoma hematological cancers occurring after SLE diagnosis, and their demographic characteristics, including sex, race/ethnicity and age at time of cancer diagnosis.

Results

A total of 15,980 patients were observed for an average of 7.5 person-years. Of these, 90% were female and the majority was Caucasian. Based on age-matched general population cancer rates, the standardized incidence ratio for hematological cancers after SLE onset was 2.9 in females (95% CI = 2.3 to 3.6) and 3.6 in males (95% CI = 2.2 to 5.5). A total of 115 hematological cancers occurred: 82 were lymphoma (75 non-Hodgkin's, seven Hodgkin's), and 33 were nonlymphoma.

Of the 33 nonlymphoma cases, 13 were of lymphoid lineage: multiple myeloma (MM, n = 5), plasmacytoma (n = 3), B-cell chronic lymphocytic leukemia (B-CLL, n = 3), lymphocytic leukemia (n = 1), and precursor cell lymphoblastic leukemia (n = 1). The remaining 20 cases were of myeloid lineage: myelodysplastic syndrome (MDS, n = 7), acute myeloid leukemia (AML, n = 7), chronic myeloid leukemia (CML, n = 2), and four unspecified leukemias.

All lymphoid malignancies occurred in female Caucasians, except for plasma cell neoplasms, where 4/5 MM cases and 1/3 plasmacytoma cases occurred in blacks (the others being Asian and Caucasian). At the time of MM diagnosis in SLE, the median age was 49 years (range 45 to 57), while for the three plasmacytoma SLE cases the median age was 35 years (range 25 to 62). In the female general population, median age at onset is 70 years for MM 1 and 55 years for plasmacytomas 2. The median age of SLE subjects at B-CLL onset was 65 years (range 58 to 83), similar to the female general population (74 years).

Of 20 myeloid malignancies, three (15%) occurred in males, and six of the 20 myeloid malignancies (30%) occurred in blacks. All seven AML cases were female, with median age at AML diagnosis of 48 years (range 34 to 72), versus 66 years in the female general population. The seven MDS cases (six females) occurred at a median age of 48 years (range 36 to 59), versus 76 years in the general population. The ages at time of diagnosis for the two CML cases (one female) were similar to the general population median (65 years).

Conclusion

In our SLE cohort, the most common nonlymphoma hematological malignancies observed were myeloid types (MDS and AML). This is in contrast to the general population, where lymphoid types are three times more common than myeloid 3. Most (80%) MM cases in our SLE cohort occurred in blacks. Most of our nonlymphoma hematological malignancy cases were younger than general population median age of onset, although this could simply reflect our cohort demographics.

Acknowledgements

Our efforts were made possible through the endorsement and support of the Canadian Arthritis Network and the Arthritis Society.

 SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations)Bethesda, MD: National Cancer InstituteHowlader N, Noone AM, Krapcho M, et alhttp://seer.cancer.gov/csr/1975_2009_pops09/<p>Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone</p>KnowlingMAHarwoodARBergsagelDEJ Clin Oncol198312552626668499<p>Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project</p>SantMAllemaniCTeranuCAngelisRDCapocacciaRVisserOMarcos-GrageraRMaynadiéMSimonettiALutzJMBerrinoFHAEMACARE Working GroupBlood20101163724373410.1182/blood-2010-05-28263220664057